JP2016006125A5 - - Google Patents

Download PDF

Info

Publication number
JP2016006125A5
JP2016006125A5 JP2015196105A JP2015196105A JP2016006125A5 JP 2016006125 A5 JP2016006125 A5 JP 2016006125A5 JP 2015196105 A JP2015196105 A JP 2015196105A JP 2015196105 A JP2015196105 A JP 2015196105A JP 2016006125 A5 JP2016006125 A5 JP 2016006125A5
Authority
JP
Japan
Prior art keywords
glp
ala
analog
intestinal
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015196105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016006125A (ja
JP6272284B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016006125A publication Critical patent/JP2016006125A/ja
Publication of JP2016006125A5 publication Critical patent/JP2016006125A5/ja
Application granted granted Critical
Publication of JP6272284B2 publication Critical patent/JP6272284B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2015196105A 2005-05-04 2015-10-01 グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ Expired - Lifetime JP6272284B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67806605P 2005-05-04 2005-05-04
US60/678,066 2005-05-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013077830A Division JP5876434B2 (ja) 2005-05-04 2013-04-03 グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ

Publications (3)

Publication Number Publication Date
JP2016006125A JP2016006125A (ja) 2016-01-14
JP2016006125A5 true JP2016006125A5 (enExample) 2016-03-10
JP6272284B2 JP6272284B2 (ja) 2018-01-31

Family

ID=36649773

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008509505A Expired - Lifetime JP5405105B2 (ja) 2005-05-04 2006-05-04 グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ
JP2013077830A Expired - Fee Related JP5876434B2 (ja) 2005-05-04 2013-04-03 グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ
JP2015196105A Expired - Lifetime JP6272284B2 (ja) 2005-05-04 2015-10-01 グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2008509505A Expired - Lifetime JP5405105B2 (ja) 2005-05-04 2006-05-04 グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ
JP2013077830A Expired - Fee Related JP5876434B2 (ja) 2005-05-04 2013-04-03 グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ

Country Status (24)

Country Link
US (7) US7563770B2 (enExample)
EP (4) EP3473646A1 (enExample)
JP (3) JP5405105B2 (enExample)
KR (3) KR101200227B1 (enExample)
CN (2) CN102659938B (enExample)
AT (1) ATE498631T1 (enExample)
AU (1) AU2006242998B2 (enExample)
BR (1) BRPI0610091B1 (enExample)
CA (1) CA2607150C (enExample)
CY (1) CY1111411T1 (enExample)
DE (1) DE602006020123D1 (enExample)
DK (1) DK1877435T4 (enExample)
EA (1) EA014184B1 (enExample)
ES (1) ES2361095T5 (enExample)
IL (3) IL186746A (enExample)
MX (1) MX2007013431A (enExample)
NO (1) NO345236B1 (enExample)
NZ (4) NZ562943A (enExample)
PL (1) PL1877435T5 (enExample)
PT (1) PT1877435E (enExample)
SI (1) SI1877435T2 (enExample)
UA (1) UA95235C2 (enExample)
WO (1) WO2006117565A2 (enExample)
ZA (2) ZA200709384B (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PT2298278E (pt) 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
WO2004019968A1 (en) 2002-08-28 2004-03-11 Dyax Corp. Methods for preserving organs and tissues
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
DE602006020123D1 (de) 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
US20070213275A1 (en) * 2006-03-10 2007-09-13 Dyax Corp. Formulations for ecallantide
BRPI0715113A2 (pt) † 2006-07-26 2013-06-04 Sandoz Ag Sandoz Sa Sandoz Ltd formulaÇço de caspofungina
EP2081555A2 (en) * 2006-09-12 2009-07-29 Cosmo Technologies Ltd. Pharmaceutical compositions for the oral or rectal administration of protein substances
AU2007319066B2 (en) * 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
US20090004243A1 (en) 2007-06-29 2009-01-01 Pacetti Stephen D Biodegradable triblock copolymers for implantable devices
KR20090035279A (ko) * 2007-10-05 2009-04-09 경희대학교 산학협력단 위장관 손상 예방 및 치료용 조성물
US20090110713A1 (en) * 2007-10-31 2009-04-30 Florencia Lim Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
CN101824087A (zh) * 2009-03-05 2010-09-08 连云港恒邦医药科技有限公司 胰高血糖素样肽-2类似物及其制备方法和用途
EP2314616A1 (en) * 2009-10-23 2011-04-27 Ferring B.V. Peptidic GLP-2 agonists
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
JP5908478B2 (ja) 2010-08-30 2016-04-26 エヌピーエス ファーマシューティカルズ インコーポレイテッドＮｐｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ｈ「Ｇｌｙ２」ＧＬＰ−２の固相合成
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
CN102212127B (zh) * 2011-05-17 2015-02-04 上海景泽生物技术有限公司 胰高血糖素样肽-2聚乙二醇结合物及其制备方法和用途
CN102924589B (zh) * 2011-08-11 2016-08-24 中肽生化有限公司 胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途
ES2687651T3 (es) 2011-09-12 2018-10-26 Amunix Operating Inc. Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
KR101895047B1 (ko) 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
CN104302408B (zh) 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
EA028929B1 (ru) 2012-05-03 2018-01-31 Зилэнд Фарма А/С Аналоги глюкагоноподобного пептида-2 (glp-2)
US20150038674A1 (en) * 2013-08-05 2015-02-05 Bayrak Bertan Boran Use of glp-2 analogues in pulmonary diseases for therapeutic purpose
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
US20160067311A1 (en) * 2014-09-10 2016-03-10 Helsinn Healthcare Sa Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
US20170087216A1 (en) * 2015-09-17 2017-03-30 Helsinn Healthcare Sa Therapeutic Uses of Elsiglutide
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN107987170B (zh) 2016-10-27 2018-12-18 浙江道尔生物科技有限公司 一种用于治疗肠道疾病的融合蛋白
AU2017373901B2 (en) 2016-12-09 2021-06-03 Zealand Pharma A/S GLP-1/GLP-2 dual agonists
WO2018104559A1 (en) * 2016-12-09 2018-06-14 Zealand Pharma A/S Glp-1/glp-2 dual agonists
WO2018104558A1 (en) * 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
KR102502040B1 (ko) * 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
WO2018142363A1 (en) * 2017-02-06 2018-08-09 Orbicular Pharmaceutical Technologies Private Limited Ready to use compositions of glp-2 analogues through self-administrable devices
IL271245B2 (en) * 2017-06-16 2023-10-01 Zealand Pharma As Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2
AR113258A1 (es) * 2017-09-28 2020-03-11 Hanmi Pharm Ind Co Ltd Conjugados persistentes de derivados del péptido 2 similar al glucagón (glp-2)
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2020020904A1 (en) 2018-07-23 2020-01-30 Zealand Pharma A/S Therapeutic uses of glp-2 agonists
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3628682A1 (en) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
US20200254065A1 (en) * 2019-02-11 2020-08-13 Opko Biologics Ltd. Long-acting glp-2 analogs
SG11202111312UA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
CN110305223B (zh) 2019-06-26 2022-05-13 重庆派金生物科技有限公司 重组串联融合蛋白制备目标多肽的方法
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
EP4069726A4 (en) 2019-12-04 2024-03-20 The Scripps Research Institute GLP2 RECEPTOR AGONISTS AND METHOD OF USE
AU2021209045A1 (en) 2020-01-13 2022-07-28 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
EP4120958B1 (en) 2020-03-18 2026-04-29 Takeda Pharmaceutical Company Limited Implantable cell chamber device and uses thereof
US20230110689A1 (en) 2020-03-30 2023-04-13 Zealand Pharma A/S Agonist combination
CN115697375A (zh) * 2020-04-03 2023-02-03 韩美药品株式会社 预防或治疗放疗、化疗或其组合引发的粘膜炎的包含glp-2衍生物或其长效缀合物的药物组合物
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CN111560061A (zh) * 2020-05-26 2020-08-21 成都圣诺生物制药有限公司 一种Gelpaglutide的制备方法
CN111560062A (zh) * 2020-05-26 2020-08-21 成都圣诺生物制药有限公司 一种Elisiglutide的制备方法
CA3182260A1 (en) 2020-06-09 2021-12-16 Gleb Feldman Manufacture, formulation and dosing of apraglutide
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
MX2023006901A (es) 2020-12-16 2023-06-26 Zealand Pharma As Uso de analogos de glp-2 en pacientes con insuficiencia renal.
IL301891A (en) * 2020-12-16 2023-06-01 Zealand Pharma As Drug composition of dual GLP-1/GLP-2 agonists
AU2022289610A1 (en) 2021-06-09 2024-01-25 The Scripps Research Institute Long-acting dual gip/glp-1 peptide conjugates and methods of use
CN115636876A (zh) * 2021-07-20 2023-01-24 重庆派金生物科技有限公司 胰高血糖素样肽-2突变体的定向化学偶联物及其应用
WO2023036862A1 (en) 2021-09-10 2023-03-16 Zealand Pharma A/S Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues
WO2023118416A1 (en) 2021-12-23 2023-06-29 Zealand Pharma A/S Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues
KR20250075601A (ko) 2022-09-30 2025-05-28 질랜드 파마 에이/에스 글루카곤-유사-펩타이드-2(glp-2) 유사체 및 단장 증후군(sbs) 치료를 위한 이의 의학적 용도
TW202436330A (zh) 2023-01-27 2024-09-16 丹麥商西蘭製藥公司 類升糖素胜肽-2(glp-2)類似物及其用於治療短腸症候群(sbs)之醫藥用途
CN116478269B (zh) * 2023-04-28 2026-07-17 成都奥达生物科技有限公司 一种长效替度鲁肽化合物
CN116751278B (zh) * 2023-06-21 2024-02-13 杭州信海医药科技有限公司 一种Glepaglutide的制备方法
WO2025141129A1 (en) 2023-12-28 2025-07-03 Zealand Pharma A/S Formulations of glucagon-like-peptide 2 (glp-2) analogues and their uses
AU2025214331A1 (en) * 2024-01-31 2026-08-13 Hangzhou Sciwind Biosciences Co., Ltd. Glucagon-like peptide 2 derivative and use thereof
WO2025181330A1 (en) 2024-02-29 2025-09-04 Vectivbio Ag Dosage regimens for glucagon-like peptide 2 (glp-2) analogs

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
JP2961045B2 (ja) 1993-02-24 1999-10-12 日清製粉株式会社 腸管粘膜増強促進剤
US6184208B1 (en) 1994-06-29 2001-02-06 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5789379A (en) 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
EP1975177B1 (en) † 1996-03-01 2011-04-13 Novo Nordisk A/S An appetite-suppressing peptide, its compositions and use
US5912229A (en) 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
EP2275438A1 (en) * 1996-04-12 2011-01-19 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
US5994500A (en) * 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
US20020025933A1 (en) 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
ATE253375T1 (de) † 1997-05-16 2003-11-15 Ontario Inc 1149336 Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
US6051557A (en) 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
EP1052994A2 (en) 1998-02-02 2000-11-22 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
AU757658B2 (en) 1998-03-09 2003-02-27 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
WO2001041779A2 (en) 1999-12-08 2001-06-14 1149336 Ontario Inc. Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment
PT1326630E (pt) 2000-09-18 2008-09-02 Sanos Bioscience As Utilização de péptidos glp-2
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
WO2002066062A2 (en) * 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
DK1360202T3 (da) * 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
JP2005506956A (ja) * 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性ｇｌｐ−１製剤
US7411039B2 (en) * 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
EP1608680A2 (en) * 2003-03-24 2005-12-28 Novo Nordisk A/S Glp-2 derivatives
EP1670515A2 (en) * 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
DK1809318T3 (da) * 2004-11-01 2013-09-08 Nps Pharma Inc Behandling af korttarmssyndrom-patienter med tyktarmskontinuitet
DE602006020123D1 (de) 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
AU2007319066B2 (en) 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
MA32970B1 (fr) 2008-12-15 2012-01-02 Zealand Pharma As Analogues du glucagon
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
CA3134906A1 (en) 2011-05-18 2012-11-22 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance

Similar Documents

Publication Publication Date Title
JP2008539713A5 (enExample)
ES2792848T3 (es) Politerapia para el tratamiento de infecciones por VHB
US10577337B2 (en) Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof
ES2647216T3 (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
US10301255B2 (en) Hepatitis B antiviral agents
MX2022010044A (es) Composicion farmaceutica que comprende microesferas de liberacion sostenida que incluyen analogo de glp-1 o sal farmaceuticamente aceptable del mismo.
RU2020109881A (ru) Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита
AU2018227849A1 (en) Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
JP2015518818A5 (enExample)
JP2014077003A5 (enExample)
US20250230181A1 (en) Pentaaza macrocyclic ring complexes possessing oral bioavailability
WO2015183794A1 (en) Tgr5 agonist complexes for treating diabetes and cancer
JPWO2019107530A5 (enExample)
RU2010113989A (ru) Применение пептида в качестве терапевтического средства
JP2011225596A5 (enExample)
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2015535243A5 (enExample)
JP2011528333A5 (enExample)
RU2015118581A (ru) Лиофилизированные препараты мелфалана флуфенамида
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2016510326A5 (enExample)
JP4632204B2 (ja) 下痢型過敏性腸症候群治療剤
EA201100565A1 (ru) Композиции и способы лечения заболеваний кишечника с использованием гранулированного мезаламина
RU2018123718A (ru) Режимы дозирования мелфлуфена для раковых заболеваний
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa